A Novel Treatment of Error Awareness for Acquired Apraxia of Speech and Aphasia: Effects of a Single-Case Experimental Design Investigation.

Am J Speech Lang PatholMay 28, 2026 (epub)
Case ReportNeurologyPhysical Medicine & Rehabilitation

Daniel Paul Salomon, Julie L Wambaugh

✦ AI-curated · Sources linked

Condensed from the publisher's abstract. An xxcode editorial summary of this publication has not been generated yet.

From the abstract

Error awareness (EA) is the ability to identify errors in one's speech productions. Persons with aphasia and apraxia of speech (A-AOS) have been found to vary widely in their EA abilities. EA, as measured by the accuracy of self-judgments of word production accuracy, has been found to be moderately associated with response to AOS treatment.

Reported results

Both participants demonstrated very large treatment-based improvements for EA in treated sets. Word production accuracy also improved for both participants' treated sets.

Authors' conclusions

TEA was a successful new intervention for these individuals with A-AOS and impaired EA.

Source

PubMed · PMID 42207961

Published in Am J Speech Lang Pathol. The text above is extracted from the publisher's own abstract and has not been edited by xxcode. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.